147 related articles for article (PubMed ID: 26178368)
1. Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG).
Nishimura Y; Jingu K; Itasaka S; Negoro Y; Murakami Y; Karasawa K; Kawaguchi G; Isohashi F; Kobayashi M; Itoh Y; Ariga T
Int J Clin Oncol; 2016 Feb; 21(1):88-94. PubMed ID: 26178368
[TBL] [Abstract][Full Text] [Related]
2. Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey.
Nishimura Y; Koike R; Ogawa K; Sasamoto R; Murakami Y; Itoh Y; Negoro Y; Itasaka S; Sakayauchi T; Tamamoto T
Int J Clin Oncol; 2012 Feb; 17(1):48-54. PubMed ID: 21607829
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
[TBL] [Abstract][Full Text] [Related]
5. Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation.
Swisher SG; Moughan J; Komaki RU; Ajani JA; Wu TT; Hofstetter WL; Konski AA; Willett CG
J Thorac Oncol; 2017 Feb; 12(2):368-374. PubMed ID: 27729298
[TBL] [Abstract][Full Text] [Related]
6. Nonsurgical management of esophageal adenocarcinoma.
Gujral DM; Hawkins MA; Leonulli BG; Ashley S; Chau I; Cunningham D; Tait D
Clin Colorectal Cancer; 2011 Sep; 10(3):165-70. PubMed ID: 21855037
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
[TBL] [Abstract][Full Text] [Related]
8. Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia.
Kawamoto T; Nihei K; Sasai K; Karasawa K
Int J Clin Oncol; 2018 Dec; 23(6):1076-1083. PubMed ID: 30066207
[TBL] [Abstract][Full Text] [Related]
9. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
[TBL] [Abstract][Full Text] [Related]
11. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients.
Sakaeda T; Yamamori M; Kuwahara A; Hiroe S; Nakamura T; Okumura K; Okuno T; Miki I; Chayahara N; Okamura N; Tamura T
Ther Drug Monit; 2008 Aug; 30(4):497-503. PubMed ID: 18641541
[TBL] [Abstract][Full Text] [Related]
12. Radiation field size and dose determine oncologic outcome in esophageal cancer.
Gemici C; Yaprak G; Batirel HF; Ilhan M; Mayadagli A
World J Surg Oncol; 2016 Oct; 14(1):263. PubMed ID: 27737673
[TBL] [Abstract][Full Text] [Related]
13. Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer.
Ishikawa K; Nakamatsu K; Shiraishi O; Yasuda T; Nishimura Y
Int J Clin Oncol; 2015 Jun; 20(3):531-7. PubMed ID: 25073955
[TBL] [Abstract][Full Text] [Related]
14. [Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer].
Lin Q; Gao XS; Qiao XY; Chen K; Wang YD; Zhou ZG
Ai Zheng; 2008 Oct; 27(10):1077-81. PubMed ID: 18851788
[TBL] [Abstract][Full Text] [Related]
15. Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study.
Hamamoto Y; Mizusawa J; Katayama H; Nakamura K; Kato K; Tsubosa Y; Ishikura S; Igaki H; Shinoda M; Fukuda H; Kitagawa Y; Ando N
Jpn J Clin Oncol; 2016 Apr; 46(4):389-92. PubMed ID: 26830150
[TBL] [Abstract][Full Text] [Related]
16. Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Kuwahara A; Yamamori M; Kadoyama K; Nishiguchi K; Nakamura T; Miki I; Tamura T; Okuno T; Omatsu H; Sakaeda T
J Exp Clin Cancer Res; 2011 Oct; 30(1):94. PubMed ID: 21970688
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
[TBL] [Abstract][Full Text] [Related]
18. A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer.
de Vos-Geelen J; Hoebers FJP; Geurts SME; Hoeben A; de Greef BTA; Voncken FEM; Bogers JHA; Braam PM; Muijs CKT; de Jong MA; Kasperts N; Rozema T; Jeene PM; Blom GJ; van Dieren JM; Hulshof MCCM; van Laarhoven HWM; Grabsch HI; Lemmens VEPP; Tjan-Heijnen VCG; Nieuwenhuijzen GAP
Acta Oncol; 2020 Aug; 59(8):895-903. PubMed ID: 32319845
[No Abstract] [Full Text] [Related]
19. Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
Kumekawa Y; Kaneko K; Ito H; Kurahashi T; Konishi K; Katagiri A; Yamamoto T; Kuwahara M; Kubota Y; Muramoto T; Mizutani Y; Imawari M
J Gastroenterol; 2006 May; 41(5):425-32. PubMed ID: 16799883
[TBL] [Abstract][Full Text] [Related]
20. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
